Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells. The annual incidence is four per 100,000 individuals. It was estimated that 19,900 new cases would be diagnosed in 2007, with 10,790 estimated deaths due to myeloma [1]. The median age at diagnosis is approximately 65 years, making it a disease that predominantly affects older patients. Although myeloma cells are chemosensitive, the median survival for patients with multiple myeloma remains less than 5 years.